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ABSTRACT 
 
Obesity is a harmful and costly condition which continues to increase in prevalence.  Co-
morbidities accompanying this disease include brain-based disorders that impact cognition and 
mood.  Anhedonia is a biobehavior associated with depression that manifests in mice as a loss of 
interest in consuming a highly palatable sucrose or saccharin solution.  Here we show that obese 
mice fed a high-fat diet (HFD), fail to exhibit an interest in saccharin (27% vs 74%) compared to 
mice fed a low-fat diet (LFD) (p < 0.007).  When HFD mice undergo a fasting period of 24 hours, 
saccharin preferences equilibrate to water consumption (51% saccharin vs 49% water).  Other 
behaviors such as immobility during the forced swim test (FST) and burrowing behavior are 
improved by fasting in HFD mice.  We have previously shown and demonstrate here that basal 
serum leptin and IL-1RA concentrations are increased in mice fed HFD for 12 weeks compared 
to mice fed LFD.  Leptin has been associated with modulation of motivation to obtain reward 
and anti-depressant activity, and IL-1RA has been implicated in the mediation of central leptin 
resistance.  To examine if these cytokines contributed to the increased saccharin consumption 
and other behaviors observed in fasted HFD mice, we measured serum concentrations during the 
fed and fasted states.  Leptin decreased, although not significantly, in mice fed a HFD (43,844 vs 
42,791 pg/mL) and LFD (8,118 vs 3,104 pg/mL) after a 24-hour fast.  IL-1RA did not 
significantly change in either group fed LFD or HFD when fasted, and IL-1β was not detectable 
in any group.  We further investigated differences in leptin, leptin receptor (LepR), IL-1RA, IL-
1R1, IL-1R2, IL1α and IL-1β brain expression in fed and fasted HFD and LFD mice utilizing 
real-time PCR (RT PCR) gene expression analysis.  A 2-fold increase in leptin expression was 
seen in both LFD (1 vs 2) and HFD (2 vs 4) after a 24 hour fast (p < 0.05).  IL-1RA expression 
was increased 2.3-fold in HFD compared to LFD in the fed state (1 ± 0.31 vs 2.26 ± 0.66) (p < 
0.05) and trended toward increasing in the HFD fed vs fasted (1.89 vs 4.16) but this was not 
significant. IL-1R1 expression was decreased in fed (0.79 ± 0.09 vs 1 ± 0.08) and fasted (0.68 ± 
0.14 vs 0.88 ± 0.07; p < 0.05) HFD mice compared to LFD mice.  IL-1R2 expression was 
decreased during fasting in mice fed HFD compared to mice fed LFD (1.013 ± 0.12 vs. 1.40 ± 
0.08; p < 0.005).  IL-1α expression was increased 1.5-fold after fasting in mice fed HFD 
compared to mice fed LFD (0.923 ± 0.14 vs. 0.59 ± 0.15; p < 0.05) and decreased by 1.6-fold 
during fasting within the LFD group compared to its fed state (0.6 ± 0.15 vs 1 ± 0.19; p < 0.05).  
Taken together, these data show that changes in brain gene expression of leptin, IL-1α, IL-1R2, 
IL-1R1 and IL-1RA occur during fasting, and that these changes may be affected by nutritional 
status and contribute to differences in saccharin preference in mice fed a HFD.  In order to 
determine if IL-1RA played a role in saccharin consumption, IL-1RA knockout mice were given 
a saccharin preference test.  Similar to mice fed HFD, IL-1RA KO mice had an aversion to 
saccharin compared to control WT mice.  IL-1RA KO mice consumed 12% saccharin solution 
compared to control WT mice that consumed 65% of their total daily fluid intake from saccharin 
solution (p < 0.005).  Taken together, these data indicate that a deviation in normal levels of 
brain IL-1RA may contribute to saccharin aversion, and that fasting has a behavioral benefit in 
mice fed HFD that may be reliant on increased leptin expression in the brain. 
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CHAPTER ONE 
INTRODUCTION 
 This section provides a review of the literature on obesity, the innate immune system, and 
related behavioral consequences of obesity.  Obesity is a state of increased lipid accumulation in 
white adipose tissue (WAT) that is linked not only to weight gain, but also to chronic, low-grade 
inflammation (Lago et al., 2007).  Over the past two decades, inflammation has been recognized 
as a major contributor to the pathogenesis of several common diseases, including atherosclerosis, 
diabetes, asthma, cancer, and obesity.  Inflammation of adipose tissue accompanies obesity and 
contributes to its sequelae (Nathan, 2008).  Recognition of the connection between obesity and 
inflammation dates back to 1993, when the inflammatory cytokine tumor necrosis factor (TNF-
α) was shown to be secreted from adipose tissue in obese rodents and contribute to insulin 
resistance (Hotamisligil et al., 1993).  Ten years later, it was determined that adipose tissue is 
infiltrated by macrophages in obese children and adults (Weisburg et al., 2003) and mice (Xu et 
al., 2003), in proportion to how far they exceed normal body weight.  These macrophages 
produce inflammatory substances that can act in the periphery and in the central nervous system.  
Recently, inflammatory changes including increased leakiness of vessels and adhesion of 
leukocytes and platelets were observed in the visceral, adipose tissue in obese but not lean mice 
(Nishimura et al., 2008).  Obesity leads to inflammation, and having excess adipose tissue can 
exacerbate obesity by dysregulating adipocyte-derived regulators of feeding (Nathan, 2008).   
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Cytokines and Obesity 
IL-1 
 Cytokines that are produced by leukocytes and exert their effects preferentially on other 
white cells are called interleukins (IL).  These mediators are also produced by and act on many 
other cells other than leukocytes (Litwack, 2006).  IL-1 is produced from two distinct genes that 
encode proteins, IL-1α and IL-1β, that share only 26% homology (Dinarello et al., 1994).  IL-1β 
is synthesized in an inactive form as a precursor that is cleaved by IL-1β converting enzyme 
(ICE) to its bioactive form (Schmidt, 1984).  A third member of the IL-1 family is a naturally 
occurring inhibitor, IL-1 receptor antagonist (IL-1RA), which blocks the binding and biological 
activity of both IL-1α and IL-1β (Cominelli et al., 1990).  The IL-1RA molecule binds 
specifically to interleukin-1 receptors (IL-1Rs), but fails to trigger internalization of the ligand-
receptor complex inhibiting initiation of intracellular responses (Arend et al., 1993).   
Two receptor isoforms have been identified and exist in both membrane-bound and 
soluble forms (Slack et al., 1993).  These include an 80 kDa type 1 IL-1 receptor (IL-1R1) 
(Resch et al., 1986; Horuk et al., 1987) and a 68 kDa type II IL-1 receptor (IL-1R2) (Re et al., 
1994).  Soluble forms of the receptors are generated by proteolysis of the extracellular domains 
and soluble IL-1R2 seems to bind to IL-1β (Symons et al., 1991), while soluble IL-1R1 seems to 
bind to IL-1ra (Svenson et al., 1993) and IL-1α (Dinarello et al., 1994).  Of the two membrane-
bound receptors, only IL-1R1 is physiologically functional, activating intercellular IL-1 signaling 
cascades.  IL-R2 acts as a decoy receptor and negative regulator of IL-1β and IL-1α because 
binding does not initiate intercellular signaling (Re et al., 1994; Labriola-Tompkins et al., 1991).  
These observations indicate that the relative proinflammatory activities of IL-1 in a diseased 
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tissue will depend on the concentrations of IL-1α, IL-1β, IL-1RA, membrane bound forms of IL-
1R1 and IL-1R2, and soluble forms of the two IL-1Rs. 
IL-1β stimulates many physiological responses including activation of the hypothalamic-
pituitary-adrenal axis (HPA), febrile response, sickness behaviors and anorexia (Sternberg et al., 
1989; MacPherson et al., 2005).  IL-β has been shown to be increased in the serum of obese 
diabetics and is related to progression of associated complications (Pickup, 2004).   
IL-1α polymorphisms have been suggested to be associated with rheumatoid arthritis and 
Alzheimer’s disease (Rainero et al., 2004).  Additionally, IL-1α is essential for maintenance of 
skin barrier function, especially with increasing age (Barland et al., 2010). 
 
IL-1β, IL-1RA, and Obesity 
 In the absence of a chronic disease state such as obesity and type II diabetes (T2D), IL-1 
plays an important role in energy homeostasis (Matsuki et al., 2003).  It has been suggested that 
IL-1β can modulate lipid metabolism by suppressing the activity of lipoprotein lipase (LPL) 
(Doerrler et al., 1994) and may regulate adipocyte function by inhibiting maturation (Gregoire et 
al., 1992).   
 IL-1 receptor antagonist levels are elevated in the circulation of patients with a variety of 
inflammatory, infectious, and post-surgical conditions (Arend, 2002), with obese patients 
reported to have a 7-fold increase in serum IL-1RA relative to controls (Meier et al., 2002).  It is 
likely that IL-1RA in the circulation diffuses into the tissues and influences the local ratio of IL-
1RA to IL-1β.  However, because of the spare receptor effect, 100-fold or greater levels of IL-
1RA over IL-1β are necessary to functionally inhibit the biologic effects of IL-1β on target cells 
(Arend, 1990).  It has been shown that IL-1RA is a pro-adipogenic factor that inhibits IL-1β  
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induced energy expenditure leading to weight gain and obesity (Perrier et al., 2006).  IL-1RA 
knockout mice are much leaner than wild type mice due to a significant decrease in fat mass, 
which is attributed to impaired lipid accumulation (Matsuki et al., 2003).  Therefore, the IL-
1β/IL-1RA system may exhibit some control on lipid metabolism through direct control of 
adipose tissue.   
The balance between IL-1RA and IL-1β levels in local tissues influences the physiologic 
or pathophysiologic effects of IL-1β.  An imbalance between IL-1β and IL-1RA is one of the 
factors influencing the course, the susceptibility to and the severity of many diseases (Arend et 
al., 2002).  In morbid obesity, leptin may exert its effects through the IL-1 pathway, and IL-1RA 
may contribute to central leptin resistance because it crosses the BBB (Guitierrez et al., 1994).  
Leptin induces IL-1RA expression in the brain including the hypothalamus (Hosoi et al., 2002), 
and injection of IL-1RA into the cerebral ventricles inhibits leptin-induced reduction in food 
intake (Luheshi et al., 1999).  IL-1RA knockout mice have an increased food intake relative to 
their body weight, but have a lean phenotype (Somm et al., 2005).  This could be a consequence 
of increased energy expenditure or a significant reduction in blood leptin levels (6-fold lower 
compared to wild type).  Circulating levels of proinflammatory cytokines including IL-1 are not 
significantly different from those in wild type mice (Somm et al., 2005) 
Long-term feeding on a HFD modulates the expression of more than 10% of genes 
expressed in the hypothalamus of rodents (DeSouza et al., 2008).  The majority of genes 
undergoing differential expression belong to families of genes with immunological function.  
Among these, a few cytokines were identified by real-time PCR, ELISA and immunoblot.  These 
cytokines included TNF-α, IL-1β, and IL-6, which were all significantly increased in the 
hypothalamus of rats fed a HFD.   
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Leptin 
Given that its absence accounts for the obese phenotype of ob/ob mice, this 16-kDa 
protein was named leptin, derived from the Greek, leptos, meaning thin (Halaas et al. 1995).  
Leptin was originally identified in 1994 as the gene responsible for the obesity syndrome in 
ob/ob mice by Freidman and colleagues (Zhang et al., 1994).  Leptin is highly conserved among 
species, and its structure is cytokine-like, particularly resembling interleukin-6 (IL-6) (Madej et 
al., 1995).  Therefore, the structure of leptin suggests that it might be classified as a cytokine.  It 
is produced by adipose tissue in proportion to body mass (Juge-Aubry et al., 2002) and is best 
known for its role in regulating satiety and energy storage in the form of fat.   
In addition to playing a key role in energy regulation, leptin regulates endocrine and 
immune functions (Faggioni et al., 2001).  Leptin levels increase acutely during infection and 
inflammation, and may represent a protective component of the host response to inflammation 
(Faggioni et al., 2001).  Leptin acts in response to challenge of the innate immune system, 
leading to increased phagocytic function in monocytes/macrophages and augmented LPS-
induced proinflammatory cytokines such as TNF-α, IL-6, and IL-12 (Matarese et al., 2005) as 
well as the anti-inflammatory cytokine IL-1RA (Dreyer et al., 2003).  Leptin deficiency increases 
susceptibility to infections and inflammatory stimuli and is associated with the dysregulation of 
cytokine production.  It is clear that leptin has many roles in mammalian physiology by the 
complex syndrome exhibited by leptin-deficient ob/ob and receptor deficient db/db mice.  These 
mice are not only obese, but have abnormalities in reproductive function (Chehab et al., 1996), 
hormone levels (Flier et al., 1998), wound repair (Frank et al., 2000), bone structure (Ducy et al., 
2000) and immune function (Howard et al., 1999).  
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Leptin receptors are richly expressed in the centers of the brain responsible for 
maintaining energy homeostasis (Friedman et al., 1998), and leptin exerts most of its classical 
regulatory roles through this system.  Leptin receptors are also expressed in peripheral tissues 
including those of the immune system such as the spleen (Gainsford et al., 1996), thymus (Fei et 
al., 1997), lung (Tsuchiya et al., 1999), and leukocytes (Cioffi et al., 1996).  Six leptin receptor 
isoforms have been identified to date, all of which have identical or nearly identical extracellular 
domains, but differ in their transmembrane and intracellular domains (Tartaglia, 1997).  Leptin 
receptor b (Ob-Rb) is the only isoform with complete transmembrane and intracellular domains 
and as such signals primarily via the JAK2-STAT3 pathway (White et al., 1997) as well as 
mitogen-activated protein kinase (MAPK) signal transduction pathways (Vaisse et al., 1996).  
The Ob-Rb is also expressed on all cells of the innate immune system (Matarese et al., 2005) and 
exerts action on the immune system via T-cells, lymphocytes, monocytes, and macrophages 
(Juge-Aubry et al., 2002).   
Ob-Rb has even been shown to be expressed in a limited population of taste cells of lean 
mice (Kawai et al., 2000).  This study, demonstrated that the taste organ is a peripheral target for 
leptin and that leptin inhibits sweet responses through activation of outward K
+
 currents in lean 
mice.  They concluded that defects in the leptin suppression system in db/db mice may lead to 
their enhanced neural and behavioral sensitivities to sweet stimuli.  When energy levels are low, 
leptin secretion decreases and various orexigenic neuropeptides are generated contributing to 
feelings of hunger.  Leptin acts through its full-length isoform functional receptor (Ob-R) 
(Matarese et al., 2005) and has been shown to cross the BBB (Banks et al., 1996) via a specific, 
saturable transport mechanism that is believed to involve leptin receptor a (Ob-Ra) (Banks et al., 
1996).  It can also cross by way of the median eminence, where its main action is in the central 
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nervous system (CNS), especially the arcuate, ventromedial, and dorsomedial hypothalamus 
(Elmquist et al., 1998).   
 
Leptin and Obesity 
 The adipocyte-derived hormone, leptin, plays a central role in energy homeostasis and 
resistance to its actions is associated with obesity (Friedman et al., 1998).  Since leptin can also 
modulate inflammation (Faggioni et al., 2001), it may integrate energy balance and systemic 
inflammation.  Leptin is involved in the pathogenesis of insulin resistance, and induces 
pancreatic β cell apoptosis and impairs β cell function via IL-1β signaling in human islets 
(Maedler et al., 2004).  The concentration of leptin in blood plasma is maintained between 1 and 
20 ng/mL in lean animal and human subjects, but it may be as high as 100 ng/mL in obese 
subjects (Maffei et al., 1995).  The circulating level of leptin reflects its production by white 
adipocytes and exhibits both long-term (days) and short-term (hours) changes.  Mechanisms that 
drive changes in fat storage regulate long-term changes in leptin production (Frederich et al., 
1995).  Not only are increased adipocytes expected to produce more leptin, but also adipocytes 
containing more fat synthesize more leptin (Hamilton et al., 1995).  Short-term changes occur 
within a few hours, independent of a change in body mass and appear to involve insulin, as 
evidenced by a positive correlation between plasma levels of leptin and insulin (Ahren et al., 
1997) and by the ability of insulin treatment to increase leptin production (Mueller et al., 1998).  
Rodents with diet-induced obesity (DIO) exhibit high plasma leptin and resistance to the 
hypermetabolic and anorexic effects of leptin (Lin et al., 2000).  Resistance to the weight-
reducing effects of leptin can contribute to the progression of obesity and unresponsiveness to 
leptin appears to involve decreased leptin transport across the BBB and impairment of Ob-Rb 
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signaling (Munzberg et al., 2005).  Behavioral depression is a manifestation of systemic 
inflammation that is augmented in the absence of leptin signaling and aimed at energy 
conservation (Romanovsky et al., 1996).  Therefore, it is possible that suppression of leptin 
production under conditions of negative energy balance augments behavioral depression as well, 
though this possibility has not been previously tested in a direct experiment.  In diet-induced 
obese animals that are unresponsive to leptin, this malfunction can result in increased behavioral 
depression of systemic inflammation (Steiner et al., 2006).   
 
Leptin and Starvation 
 During fasting or starvation, leptin levels drop disproportionately to the decrease in 
adipose tissue mass and the correlation between leptin levels and fat stores is lost (Ahima et al., 
1996).  During starvation, leptin is not only an indication of energy reserve, but a neuroendocrine 
signal that is critical for the brain to initiate adaptive responses to starvation including metabolic, 
endocrine, and immunological changes.  Suppression of immune, reproductive, and thyroid 
function and stimulation of the HPA axis are changes that are induced by starvation (Schwartz et 
al., 1997).  A consequence of prolonged fasting is lymphoid atrophy, suggesting that leptin may 
be required to maintain normal lymphoid tissue.  This is substantiated in that spleen and thymus 
weight, as well as thymocyte number were normalized in starved ob/ob mice treated with leptin 
(Howard et al., 1999).  In a study by Mito et al (2004), control mice and mice fed a HFD were 
fasted for 48 hours and weights of immune organs, cytokine production and proliferation of 
cultured splenocytes were measured.  Although starvation of the control mice dramatically 
reduced all three parameters, these levels returned to those of free-feeding groups with 
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exogenous leptin administration.  However, these effects of leptin were not observed in obese 
mice.  
 
Leptin and Reward 
Food restriction of experimental animals has been historically imposed to increase the 
occurrence of the behaviors the experimenters sought to study.  Ferster and Skinner (1957) 
observed that response rates on different schedules of reinforcement in pigeons were 
significantly increased by restriction of their body weights.  They described an inverse 
relationship between the birds’ body weight and their response for food pellets.  Obesity may be 
partly related to reward and hedonic mechanisms and a failure of regulation of the reward 
systems.  Food deprivation or negative energy balance, promotes responding for foods and other 
reinforcements.  Our current knowledge is that negative energy balance leads to lower levels of 
circulating leptin, pointing to the hypothesis that low levels of this hormone might be associated 
with an increased response to obtain rewards (Figlewicz et al., 2009).  The corollary hypothesis 
is that increased levels of leptin might be sufficient to attenuate response to a reward.   
The major neurotransmitter pathways associated with motivation and hedonics include 
mesolimbic dopamine (DA) and certain CNS opioid pathways (Figlewicz et al., 2009).  
Activation of midbrain DA neurons has been implicated in the motivating, rewarding, 
reinforcing and incentive salience properties of natural stimuli such as food and water (Berridge 
et al., 1998), as well as drugs of abuse (Smith, 1995).  In human (Wang et al., 2001) and animal 
studies (Bina et al., 2000), changes in central DA have been suggested to contribute to the 
development of obesity.  Therefore, it is possible that dysregulation of these circuits may 
adversely affect body weight regulation and that obesity is capable of altering processes within 
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the endogenous reward system of the brain.  Sipols and colleagues demonstrated suppression of 
acute sucrose licking and sucrose self-administration with intraventricular leptin administration 
(Figelwicz et al., 2006) in rats fed chow ad libitum.  Taken together, these results indicate that 
leptin, across a concentration range from fasting to free-feeding to elevated can modify behaviors 
that reflect acute and learned reward evaluation independent of their regulatory actions on body 
mass and adiposity.   
There is direct evidence that leptin decreases DA release and the electrical activity of DA 
neurons, resulting in decreased locomotor activity and decreased intake of palatable substances 
(Hommel et al., 2006).  In a study that used rats fed HFD for an extended period of time, sucrose 
self-administration decreased.  Plasma leptin levels were increased after 3 months (Davis et al., 
2008).  It could be inferred from this study that a “contrast effect” for food occurred and that the 
difference in response to sucrose was due to the already present palatable HFD.  Consistent with 
this, DA turnover in the nucleus accumbens (NAc) was substantially decreased in the HFD 
relative to LFD.  Other studies suggest that leptin may have trophic effects on DA neurons; 
therefore, models of extreme starvation, leptin resistance, or obesity may result in impaired DA 
neuronal function and signaling (Weng et al., 2007).  Leptin effects on reward circuitry may be 
bimodal, such that low concentrations of leptin sustain dopaminergic neuronal viability and 
intermediate physiological levels suppress reward function but elevated levels, linked to 
resistance and metabolic pathophysiology, lead to impaired dopaminergic function.  This theory 
may provide a link between obesity and common psychiatric disorders such as depression and 
drug addiction (Figlewicz et al., 2009).   
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Cytokine-Induced Sickness Behavior 
 Sickness behavior refers to a coordinated set of behavioral changes that develop during 
the course of an infection.  At the molecular level, these changes are caused by the effects of pro-
inflammatory cytokines, such as IL-1β and TNF-α in the brain (Dantzer, 2001).  Symptoms of 
infection and inflammation include fever and other physiological and behavioral changes.  A sick 
individual may experience weakness, malaise and inability to concentrate.  Depressed mood, 
manifesting as decreased interest in physical surroundings and normally pleasurable food and 
drink, may occur as well.  The individual becomes preoccupied with their own body and the 
suffering that they are experiencing.  This constellation of nonspecific symptoms is referred to as 
“sickness behavior” (Dantzer, 2001).  In mice, injection of IL-1β or TNF-α causes a behavioral 
inclination to stay in the corner of their home cage in a hunched posture and show little or no 
interest in their physical and social environment.  These animals also show decreased motor 
activity, social withdrawal, reduced food and water intake, increased slow-wave sleep and 
altered cognition (Dantzer et al., 2007).  Anti-inflammatory cytokines such as IL-1RA and IL-10 
regulate the intensity and duration of sickness behavior, possibly by inhibiting proinflammatory 
cytokine production and attenuating pro-inflammatory cytokine signaling (Heyen et al., 2000; 
Arakawa et al., 2009).  In particular, intracerebroventricular (ICV) administration of IL-10 or 
insulin-like growth factor (IGF-1) attenuates behavioral signs of sickness induced by centrally 
injected lipopolysaccharide (LPS) (Bluthe et al., 1999).  These data indicate that in the brain, the 
natural balance between pro-and anti-inflammatory cytokines regulate the intensity and duration 
of the response to immune stimuli.  
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In the brain 
Soluble mediators released from macrophages during inflammation, such as IL-1β, IL-6, 
TNF-α, and the interferons (IFN) can act on the brain in several ways.  Primary afferent neurons 
innervating the body site where the inflammation is transducing their signal to the brain.  
Additionally, in the humoral pathway, Toll-Like Receptors (TLRs) on macrophage-like dendritic 
cells located in the circumventricular organs and the choroid plexus outside the BBB, respond to 
circulating pathogen-associated molecular patterns (PAMPs) by producing pro-inflammatory 
cytokines which can pass the BBB and enter the brain by volume diffusion (Quan et al., 1998).  
A third pathway comprises cytokine transporters at the BBB.  Pro-inflammatory cytokines 
overflowing in the systemic circulation can gain access to the brain through saturable transport 
systems (Banks et al., 2006).  Finally, a fourth pathway involves IL-1 receptors that are located 
on perivascular macrophages and endothelial cells of brain venules (Schiltz et al., 2002; 
Konsman et al., 2004).   
Molecular biology studies have demonstrated that peripheral cytokines induce the 
synthesis and release of cytokines in the brain by microglial cells (Gatti & Bartfai, 1993; Laye et 
al., 1994).  For instance, administration of IL-1RA into the lateral ventricle of the brain to block 
brain IL-1 receptors abrogated the depressive effect of peripherally administered IL-1 on social 
exploration in rats exposed to a juvenile (Kent et al., 1992).  The brain circuitry that mediates 
various behavioral actions of cytokines is not completely known.  Different behaviors may be 
mediated in different brain areas, but ultimately the site of action of the cytokine message 
depends on the localization of cytokine receptors or receptors for intermediates such as 
prostaglandin E2 (Dantzer et al., 2007).  IL-1 receptors were first localized in the granule cell 
layer of the dentate gyrus, the pyramidal cell layer of the hippocampus and the anterior pituitary 
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gland (Parnet et al., 2002).  More recently, they were identified in endothelial cells of brain 
venules throughout the brain, at a high density in the preoptic and supraoptic areas of the 
hypothalamus and the subfornical organ, and a lower density in the paraventricular 
hypothalamus, cortex, nucleus of the solitary tract and ventrolateral medulla (Konsman et al., 
2004).   
 
Role for cytokines in depression and relation to obesity 
Depression is the most prevalent and life-threatening mental disorder with an overall 
lifetime prevalence rate of 20% of the population worldwide (Lu, 2007).  Obesity has been found 
to be associated with negative health outcomes (Must et al., 1999; Pi-Sunyer, 1993), functional 
impairment (Fontaine & Barofsky, 2001) and increased mortality (Allison et al., 1999).  Obesity 
and depression may perpetuate one another; in that obesity may increase the risk for depression 
and depression may promote obesity.  Understanding and managing the mechanisms that link 
obesity and depression is crucial to the treatment of individuals who are afflicted with both 
conditions.   
The HPA axis has been suggested as a possible neuroendocrine link between depression 
and the development of obesity.  It has been suggested that antidepressants may exert their 
primary effect through regulation and normalization of the HPA response (Holsboer & Barden, 
1996) and that failure to regulate the HPA response during treatment elevates the risk for 
depressive relapse (Holsboer, 2000).   
The contribution of pro-inflammatory cytokines such as TNF-α, IL-1, IL-6 and IFN-γ to 
the development and pathogenesis of depression has been examined (Kenis & Maes, 2002).  
Increased inflammatory responses have been found in depressed individuals (Carney et al., 2002) 
 14 
and this may be exaggerated if obesity is also present (Miller et al., 2002).  IL-6 levels decrease 
with selective serotonin reuptake inhibitor (SSRI) treatment in patients with major depressive 
disorder (MDD) (Basterzi et al., 2005).   
It has also been suggested that the enzyme indoleamine 2,3-dioxygenase (IDO), an 
enzyme that converts tryptophan to kynurenine, plays a key role in inflammation induced 
depression.  When tryptophan is shuttled down the kynurenine pathway, there is less tryptophan 
available to make serotonin (5-HT).  This resembles tryptophan depletion, which is used as an 
experimental paradigm to induce depressive symptoms in susceptible individuals (Neumeister et 
al., 2003).  In microglia and macrophages, IDO expression is induced by Th1 cytokines, IFN-γ, 
IL-1β, and TNF-α, and inhibited by Th2 cytokines, IL-4 and IL-10 (Muller & Schwartz, 2007).  
Therefore, excess inflammation may reduce 5-HT levels through activation of this pathway in 
central and peripheral macrophages, contributing to depression.   
Current treatment of depression is largely prescription of antidepressants that exert their 
therapeutic effects by promoting monoaminergic neurotransmission (Berton et al., 2006).  
However, this treatment does not fulfill expectations in terms of efficacy, onset of action and 
tolerability.  Antidepressants have also been shown to inhibit IFN-γ induced microglial 
production of IL-6 and nitric oxide (Hashioka et al., 2007) suggesting that inhibition of brain 
inflammation may be one mechanism of action of antidepressants.   
When activation of the peripheral immune system continues unabated, immune signaling 
to the brain can lead to an exacerbation of sickness and the development of symptoms of 
depression in vulnerable individuals.  This may account for the increased prevalence of clinical 
depression in physically ill people (Dantzer et al., 2007).  The similarity between the symptoms 
of cytokine-induced sickness behavior and depression are abundant.  In both cases, there is 
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withdrawal from the physical and social environment that is accompanied by pain, malaise and 
decreased reactivity to reward (anhedonia) (Dantzer et al., 2007).  Importantly, components of 
sickness behavior, such as decreased preference for sweet solutions and reduced social 
exploration, are improved by anti-depressant treatment (Yirmiya et al., 1999).  Major depressive 
disorders are more prevalent in patients afflicted with conditions that lead to chronic 
inflammation, including cardiovascular disease, T2D, rheumatoid arthritis and obesity compared 
to the general population (Markowitz et al., 2008).   
In the absence of any knowledge of the causal factors of depression, most animal models 
of depression are based on behavioral and pharmacological analogies (Dantzer, 2001).  At the 
behavioral level, the two main symptoms that are usually considered include the deficit in 
escape/avoidance learning and anhedonia which is the diminished ability to experience normally 
pleasurable stimuli.  Attenuated response to a saccharin solution in response to LPS indicating 
anhedonia was observed and reconciled by chronic but not acute treatment with the 
antidepressant drug Imipramine (Yirmiya, 1996).  Depression may represent a maladaptive 
version of cytokine-induced sickness occurring when the activation of the innate immune 
response is increased in intensity and/or duration or takes place in the context of an increased 
vulnerability to depression (Nemeroff & Vale, 2005).   
An example of how inflammation can modulate depression is a study that indicated that 
aged mice were more sensitive than young adults to not only LPS-induced sickness behavior but 
also LPS-induced depressive-like behavior, and this is associated with an exaggerated 
inflammatory response in the brain.  However, in the absence of an acute immune stimulation, 
aged mice do not differ from young adults in their behavior in animal models of depression 
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(Godbout et al., 2008).  In summary, in this study, their increased inflammatory status remains 
behaviorally silent until it is challenged.   
Chronic stress acts as a predisposing factor to the onset of depression in humans 
(McEwen, 2004).  Rats or mice exposed to chronic unpredictable stress or chronic social defeat 
stress develop behavioral deficits and endocrine abnormalities, mimicking symptoms of human 
depression and showing decreases in leptin levels in the plasma (Lu et al., 2006).  The 
observation that low circulating leptin levels in animal models of depression indicates that leptin 
insufficiency may underlie behavioral deficits.  Systematic administration of leptin in normal 
mice can reverse the chronic stress-induced decrease in sucrose preference (Lu et al., 2006).   
Another symptom of clinical depression that can be modeled in rodents is behavioral 
despair, which can be measured and assessed with a forced swim test (FST) and tail suspension 
test (TST).  These tests have high predictive validity for antidepressant activity and have been 
used for screening of antidepressant drugs (Cryan et al., 2005a,b).  Systemic leptin 
administration was found to produce a dose-dependent reduction of the duration of immobility in 
both tests (Lu et al., 2006; Kim et al., 2006).  These data support the view that leptin may have 
antidepressant-like efficacy when functioning adequately in homeostatic proportions.  Genetic 
deletion of the leptin receptor or pharmacological inhibition of leptin signaling in specific brain 
areas may help to determine whether a reduction in leptin signaling can directly lead to 
depressive behaviors (Lu et al., 2006).   
 
Motivational Aspects of Sickness Behavior 
 The motivational interpretation of sickness behavior is that it is not the consequence of 
physical debilitation caused by the disease process, but the expression of a highly organized 
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strategy enabling the organism to fight infections (Dantzer, 2001).  Therefore, sick individuals 
should be able to reorganize their behavior depending on the consequences and internal 
constraints to which they are exposed.  The flexibility to do this is characteristic of what 
psychologists call motivation (Dantzer, 2001).  The first evidence that sickness behavior is the 
expression of motivational state rather than the consequence of weakness was provided in a 
series of experiments designed to search for motivational signal for thirst (Miller, 1964).  In 
these experiments, rats injected with bacterial endotoxin stopped pressing a bar for water but, 
when given water, ingested substantial amounts but to a lesser extent than normally.  An 
important characteristic of motivational state is that it competes with other motivational states for 
behavioral output.  The normal expression of behavior requires a hierarchical organization of 
motivational states that is continuously updated according to fluctuations in the internal state and 
occurrence of external events (Dantzer, 2001).  Fatigue symptoms such as lack of energy and 
loss of interest occur very frequently in depressed patients.  These symptoms are incorporated in 
the basic description of depressive episodes, and in fact, in the 10
th
 revision of the International 
Classification of Disease, the entry for “Depression” begins with the statement that “the subject 
suffers from a lowering of mood, reduction of energy, and decrease in activity.  Capacity for 
enjoyment, interest and concentration are impaired, and marked tiredness after even minimum 
effort is common.”   
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CHAPTER TWO 
METHODOLOGY 
Materials 
All reagents and chemicals were purchased from Sigma-Aldrich (St. Louis, MO) except 
IL-1RA (MRA00) IL-1β (MLB00B), and leptin (MOB00) ELISA, R&D Systems (Minneapolis, 
MN).  High-Capacity cDNA Reverse Transcription Kit (PN 4368813), Applied Biosystems 
(Foster City, CA). 
 
Animals 
 Animal use was conducted in accordance with the Guide for the Care and Use of 
Laboratory Animals as we have described (Johnson et al., 2007) and also approved by the 
University of Illinois IACUC. C57BL/6J and B6.129S-Il1rntm1Dih/J (IL-1RA knockout) male 
mice were bred in house.  All knockout mice were bred on a C57BL/6 background.  Mice on 
diets were either bred in house or purchased from Jackson Laboratories (Bar Harbor, ME).  Mice 
were housed in standard shoebox cages and allowed water and food ad libitum.  Housing 
temperature (22.2°C) and humidity (45-55%) were controlled as was a 12/12-h reversed dark-
light cycle (2000-0800).  Where required, mice were sacrificed by CO2 asphyxiation. 
 
Diets 
Chow was closed source NIH-31 7013 from Teklad (Indianapolis, IN).  Experimental 
diets were open source uniform-base diets.  These diets contained either 10% fat (D12450B, 
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Research Diets) or 60% fat (D12492, Research Diets) (New Brunswick, NJ).  Diets were fed to 
mice for 12 weeks beginning at the age of 4 weeks. 
 
Blood Glucose 
After a 24 hour fast, blood was collected from the lateral saphenous vein and blood 
glucose measured using a FreeStyle Freedom
® glucometer (Abbott) as per manufacturer’s 
instructions as we have described (O’Connor et al., 2005) 
 
Behavior 
Saccharin preference test 
The saccharin preference test was used to measure anhedonia.  To examine this behavior, 
mice were housed singly in standard cages fitted with adapted wire tops to allow access to two 
fluids: water or a 0.4% sodium saccharin solution (Sigma-Aldrich, CN 4-7839).  Prior to 
experimental treatment, mice were exposed to two bottles of water in order to acclimate them to 
the presence of two fluid sources in the cage.  Following a three day acclimation period, one of 
the two bottles in each mouse’s wire top cage was replaced with a 0.4% sodium saccharin 
solution, place preference was accounted for by alternating the position of saccharin solution and 
water per cage, and fluid levels were monitored and recorded twice daily to measure total daily 
saccharin solution and water consumption for a total of 5 days during the fed state or 1 day after 
a 24 hour fast.  Two independent studies were performed to measure saccharin preference in fed 
and fasted mice.  Results are expressed as a percentage of total daily fluid consumption over the 
course of 5 days or 1 day and shown as means ± SEM.  Food consumption and body weight were 
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also measured during these two independent studies, and results are expressed as average food 
intake in grams per day and average body weight change per day.   
 
Forced swim test 
The forced swim test (FST) was conducted as described by Porsolt (2000). Briefly, each 
mouse was placed individually in a cylinder (diameter: 16cm; height: 31cm) containing 15cm of 
water maintained at 25  ± 1 C. The water was changed and the cylinders were cleaned thoroughly 
between testing sessions. Mice were tested for 6 min and then returned to their home cage. The 
duration of immobility was evaluated during the last 5 min of the test.  
 
Burrowing 
Lab-made cylindrical burrows were placed in the home cage 24 hours prior to testing.  
On the day of the test, mice were single housed and burrows were filled with 200 g of food 
pellets and placed along the wall of a clean cage with a thin layer of bedding, with the closed end 
of the burrow against the back wall of the cage.  Food was removed from the hopper, but water 
was still provided ad libitum.  The test was started 3 hours before the dark cycle and total amount 
burrowed was measured by weighing the amount displaced from the burrow and subtracting that 
from the total amount given at the start of the test, at 2 and 24 hours.   
 
Cytokine measurements 
All cytokine measurements were performed using commercially available ELISA (R&D 
Systems) on serum from the inferior vena cava from expired mice.  Blood was allowed to clot at 
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room temperature for 2 hours, and then centrifuged at 2,000 x g at 4°C for 20 min.  Remaining 
serum was extracted from the sample and used for analysis. 
 
 
Real-time RT PCR 
RNA isolation and real-time RT PCR was performed as we have described (Sherry et al., 
2007).  In brief, TaqMan Gene expression primer for IL-1β (Mm99999061_mH), IL-1RA 
(Mm01337566_m1), leptin (Mm00434759_m1), leptin receptor (Mm00440181_m1), IL-1R1 
(Mm00434237_m1), IL-1R2 (Mm00439622_m1), and IL-1α (MM99999060_m1) were used in 
real-time RT PCR performed on a 7900 HT Fast Real-Time PCR System (Applied Biosystems) 
using TaqMan Universal PCR Master Mix.  To normalize gene expression, a parallel 
amplification of endogenous β-actin (Mm00607939_s1) was performed with TaqMan Gene 
Expression primer.  Reactions with no reverse transcription and no template were included as 
negative controls.  Relative quantitative evaluation of target gene levels was performed by 
comparing threshold cycle (ΔCt).   
 
Statistical analysis 
The experimental design for behavioral experiments was a completely randomized design, 
with a 2 x 2 factorial arrangement of treatments (2 levels of pretreatment and 2 levels of 
treatment).  All data were analyzed using the two way (with or without repeated measures) 
ANOVA procedure of Sigma Plot (San Jose, CA).  The statistical model for saccharin preference 
included the effects of diet/phenotype x day.  Post hoc comparisons of individual group means 
were performed with the Tukey’s test.  Statistical significance was denoted at p < 0.05. 
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CHAPTER THREE 
RESULTS 
 
Saccharin preference is decreased in mice fed a high-fat diet (HFD) 
The saccharin preference test is a measure of anhedonia in rodents, and the preference for 
sweet solutions has been shown to be decreased during inflammation or infection (Dantzer, 
2001).  Mice fed HFD display an aversion to saccharin solution compared to control mice fed a 
LFD, which show a significant preference for the saccharin solution (Fig.1).  After 5 days of free 
access to both saccharin and water, mice fed HFD consumed less saccharin solution as a 
percentage of total fluid intake (27% vs. 74%) [F= 20.761, p < 0.0001] compared to LFD fed 
mice.  Two-way ANOVA with one factor repetition (diet x mouse x day) of saccharin preference 
revealed significant diet interactions [F = 9.587, p = 0.007]. 
The body weights of LFD and HFD mice during the 5 day saccharin preference test are 
presented in Fig. 2.  Two-way repeated measures ANOVA (one factor repetition) revealed 
significant interactions between diet and day [F = 4.590, p = 0.007] on day 5 alone.   Mice fed 
HFD had a significantly increased weight gain compared to mice fed a LFD [F = 3.113, p = 
0.034] on day 5 of the test.  However, food intake does not significantly change over the 5 day 
measurement period in either LFD or HFD fed mice.  Based on this finding, we can conclude 
that saccharin preference does not influence food intake in either group. 
The total food consumption measurements indicate that there is no main effect of diet on 
food consumption in HFD or LFD fed mice during the 5 day saccharin preference, although there 
is a statistical significance in food consumption between LFD and HFD fed mice on day 1 of the 
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saccharin preference test [p = 0.006] (Fig. 3).  Taken together these findings indicate that mice 
fed HFD exhibit a saccharin aversion compared to mice fed LFD without influencing overall 
food intake. 
 
Burrowing is decreased in mice fed HFD 
 Burrowing behavior is a sensitive method for detecting behavioral dysfunction because 
all rodents display burrowing behavior.  The test is sensitive to prion disease in mice, mouse 
strain differences, lesions of the hippocampus and prefrontal cortex in mice, and effects of LPS 
and IL-1β in rats (Deacon, 2006).  HFD fed mice burrow significantly less than LFD fed mice as 
shown in Fig. 4.  Two hours after introduction of the burrowing material, HFD fed mice 
burrowed only 25.4 g of material compared to LFD fed mice which burrowed 46.5 g [F = 11.149, 
p < 0.02].  By 24 hours, HFD fed mice still exhibited decreased burrowing compared to LFD 
[59.9 g vs 89.8 g; p < 0.02]. 
 
Saccharin aversion is decreased in HFD mice after 24 hour fast. 
HFD and LFD fed mice were fasted for 24 hours, then saccharin preference was 
measured.  In mice fed a HFD, saccharin preference increased to 51% of the total daily fluid 
intake, while mice fed a LFD only increased to 84% of the total daily intake after fasting (Fig. 5).  
There is a statistically significant difference in saccharin consumption [F = 10
-40
, p < 0.001] and 
water consumption [F = 10
-40
, p < 0.001] in the HFD vs LFD fed mice.  However, there was no 
significant difference between water and saccharin consumption within the HFD fed group.  
Taken together, these findings indicate that fasting HFD fed mice for 24 hours increases 
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saccharin preference, although not significantly different from water consumption.  This 
indicates that there is no longer a saccharin aversion in HFD fed mice when fasted. 
 
Burrowing is increased in HFD mice after 24 hour fast 
 In mice fed a HFD, burrowing increases after a 24 hour fast at both 2 [25.43 ± 5.04 vs. 
73.26 ± 11.9g, p < 0.005] and 24 hours [59.98 ± 10.4 vs. 93.86 ± 4.5g, p < 0.001] (Fig. 6).  Mice 
fed a HFD burrow similar amounts to mice fed a LFD after a 24 hour fast.  These results indicate 
that fasting HFD mice for 24 hours completely restores burrowing behavior to that of control 
mice. 
 
Immobility in the forced swim test (FST) decreases after fasting in LFD and HFD fed mice 
 FST is a sensitive test stimuli that provokes depressive-like behavior, measuring a 
behavioral dimension that is relevant to depression (Cryan et al., 2005).  In the fed state, HFD 
mice were immobile for an average of 4:06 minutes, which is not significantly different from 
mice fed a LFD who were immobile for an average of 4:16 minutes (Fig. 7).  However, once 
fasted, both groups had a significant decrease in immobility [3:02 vs 3:31; F = 29.295, p < 0.001], 
compared to their respective fed groups.   
 
HFD increases serum leptin and IL-1RA, which are not affected by fasting.  
Mice fed a HFD for 12 weeks have a 5-fold increase in serum leptin concentration [F = 
323.004, p < 0.001] and a 1.5-fold increase in serum IL-1RA [F = 6.546, p < 0.016] compared to 
mice fed a LFD (Table 1).  After a 24 hour fast, leptin and IL-1RA in the serum are not 
significantly changed in HFD mice.  IL-1β is not detectable in any group.  These findings 
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indicate that a change in peripheral leptin, IL-1RA, and IL-1β may not contribute to the 
behavioral changes observed in fasted HFD fed mice. 
 
Body weights decrease after a 24 hour fast in both LFD and HFD fed mice. 
 Mice fed LFD lose a significant amount of body weight during a 24 hour fast, decreasing 
from 30.8 ± 0.6g to 25.2 ± 1.31g [F = 27.914, p < 0.001].  Mice fed HFD also lose a significant 
amount of body weight during a 24 hour fast, decreasing from 49.7 ± 0.96g to 47.2 ± 6.7g 
[p<0.05] (Table 2).  The extent of fasting induced weight loss in HFD fed mice is less than that 
observed in mice fed a LFD.  As expected, HFD fed mice weigh more in both the fed and fasted 
states compared to mice fed a LFD [p < 0.001].   
 
Blood Glucose decreases after a 24 hour fast in both LFD and HFD fed mice. 
 When LFD fed mice are fasted for 24 hours, their blood glucose decreases significantly 
from 147.7 ± 5.44 to 70 ± 0.33 dg/mL [F = 127.518, p < 0.001].  Similarly, when mice fed a 
HFD are fasted for 24 hours, their blood glucose decreases from 176 ± 6.66 to 121 ± 0.81 dg/mL 
[p < 0.05] (Table 3).  Mice fed a HFD have a significantly higher blood glucose in both the fed 
and fasted states compared to mice fed a LFD [F = 45.98, p < 0.001]. 
 
Brain based cytokine expression changes after a 24 hour fast. 
Brain based gene expression was analyzed in mice fed HFD or LFD during a fed period 
(ad libitum) and a fasted period (24 hours).  The results of RT PCR gene expression analysis of 
several genes including leptin, leptin receptor (Lep R), IL-1RA, IL-1R1, IL-1R2, IL-1α and IL-
1β are shown in Fig. 8-12.  As shown in Fig. 8, mice fed LFD, had a 2-fold increase in leptin 
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after fasting [1 ± 0.15 vs 2.18 ± 0.34 Δ mRNA, p < 0.05] and mice fed a HFD had a 2 –fold 
increase [1.94 ± 0.51 vs 4.08 ± 0.34 Δ mRNA p < 0.05] as well.  IL-1α expression was increased 
1.5-fold during fasting in mice fed HFD compared to mice fed LFD [0.923 ± 0.14 vs. 0.59 ± 0.15 
Δ mRNA, p < 0.05] and decreased by 1.6-fold during fasting within the LFD group compared to 
its fed state [0.6 ± 0.15 vs. 1 ± 0.19 Δ mRNA, p < 0.05) as shown in Fig. 9.  IL-1R2 was 
decreased during fasting in mice fed HFD compared to mice fed LFD (1.013 ± 0.12 vs. 1.40 ± 
0.08 Δ mRNA, p < 0.005) as shown in Fig. 10.  IL-1R1 was decreased in the fed [0.79 ± 0.09 vs. 
1 ± 0.08 Δ mRNA, p < 0.05] and fasted [0.68 ± 0.14 vs 0.88 ± 0.07 Δ mRNA, p < 0.05] in HFD 
mice compared to LFD mice as shown in Fig. 11.  IL-1RA was increased 2.3-fold in HFD 
compared to LFD in fed [1 ± 0.31 vs 2.26 ± 0.66 Δ mRNA, p < 0.05] and 2.43-fold in the fasted 
state [1.89 ± 0.16 vs 4.16 ± 0.67 Δ mRNA] as shown in Fig. 12, although the latter was not 
significant.  There were no differences in Lep R expression between HFD and LFD and no 
differences due to fed/fasted state (data not shown).  For IL-1β, no differences in gene expression 
between HFD and LFD or fed and fasting states were observed (data not shown).  Leptin 
expression in mice fed a HFD was the only gene to significantly increase expression from fed to 
fasting.  Taken together, these data show that changes in brain gene expression of leptin, IL-1α, 
IL-1R2, IL-1R1 and IL-1RA occur during fasting, and these changes may be affected by 
nutritional status and contribute to differences in saccharin preference in mice fed HFD. 
 
Saccharin preference is decreased in IL-1RA KO mice.. 
  In order to determine if IL-1RA plays a role in saccharin preference, IL-1RA KO mice 
were given a saccharin preference test over the course of 5 days.  Similar to mice fed a HFD, IL-
1RA KO mice had an aversion to saccharin compared to control wild-type (WT) mice (Fig. 13).  
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IL-1RA KO mice consumed 12% saccharin solution compared to control WT mice that 
consumed 65% of their total daily intake from saccharin solution.  The mean values of saccharin 
consumption and water consumption in IL-1RA KO are significantly decreased [F = 729.97, p < 
0.001; F = 29.52, p < 0.006] compared to WT mice.  Taken together, these data indicate that 
depletion of IL-1RA may contribute to saccharin aversion. 
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CHAPTER FOUR 
TABLES AND FIGURES 
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Fig. 1. Saccharin preference is decreased in mice fed a high-fat diet. Mice were fed a 60% fat 
diet (HFD) or a 10% fat diet (LFD) and saccharin preference was measured utilizing a 2-bottle 
test for 5 days.  Results are expressed as a percentage of daily consumption over 5 days, means ± 
SEM; n=10; *p < 0.007, LFD saccharin vs HFD saccharin, 
a
p < 0.05, HFD water vs saccharin, 
b
p 
< 0.001, LFD water vs. saccharin.    
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Fig. 2. Saccharin preference test does not induce weight changes in HFD or LFD fed mice. 
Mice were fed HFD or LFD and saccharin preference was measured utilizing a 2-bottle test for 5 
days. During this test, body weights were taken daily.  Results are expressed as an average of 
body weight change in grams per day, means ± SEM; n = 4, *p < 0.05 factor effect of day. 
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Fig.3. Saccharin preference test does not affect food intake in HFD and LFD mice. Mice were 
fed HFD or LFD and saccharin preference was measured utilizing a 2-bottle test for 5 days. 
During this test, food weights were taken daily.  Results are expressed as an average of food 
intake in grams per day, means ± SEM; n = 4,*p < 0.05, LFD vs HFD on day 1. 
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Fig.4. Mice fed LFD exhibit increased burrowing compared to mice fed HFD at both 2 and 24 
hours.  Mice were fed HFD for at least 12 weeks or LFD for 12 weeks and burrowing behavior 
was measured at 2 and 24 hours after introduction of burrowing tubes and material. Results are 
expressed as material burrowed in grams, means ± SEM; n = 4, *p < 0.02 LFD vs HFD at 2 and 
24 hours.  
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Fig. 5. Saccharin preference is increased in HFD mice after 24 hour fast.  LFD and HFD fed 
mice were fasted for 24 hours and then saccharin preference was measured utilizing a 2-bottle 
test over 1 day. Results are expressed as a percentage of daily consumption over 1 day, means ± 
SEM; n = 8 per group, *p < 0.001, LFD water vs HFD water; LFD saccharin vs HFD saccharin, 
a
p < 0.001, LFD saccharin vs water. 
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Fig. 6. Burrowing activity in HFD increases after fasting at 2 and 24 hours.  Mice were fed 
HFD or LFD for 12 weeks, and then fasted for 24 hours.  Burrowing behavior was measured at 2 
and 24 hours after introduction of burrowing tubes and material. Results are expressed as 
material burrowed in grams, means ± SEM; n = 8. 
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Fig.7. Immobility in the forced swim test decreases in HFD and LFD fed mice when fasted. 
LFD and HFD fed mice were fasted for 24 hours and then behavioral despair was measured 
utilizing the forced swim test (FST). Results are expressed as total seconds of immobility during 
a 6 minute test period, means ± SEM; n = 8;*p < 0.05, LFD fed vs LFD fasted, **p < 0.001, 
HFD fed vs HFD fasted. 
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Fig. 8. Leptin expression in brain.  Real-time RT-PCR was used to quantify expression in brains 
of mice fed LFD or HFD for 12 weeks and in mice fasted for 24 hours.  Results are expressed as 
relative change in mRNA expression, means ± SEM; n = 8 per group; 
a
p <  0.05, 
 
LFD fed vs 
LFD fasted; HFD fed vs HFD fasted. 
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Fig. 9. IL-1α expression in brain. Real-time RT-PCR was used to quantify expression in brains 
of mice fed LFD or HFD for 12 weeks and in mice fasted for 24 hours.  Results are expressed as 
relative change in mRNA expression, means ± SEM; n = 8 per group; *p < 0.05, LFD fasted vs 
HFD fasted; 
a
p < 0.05, LFD fed vs LFD fasted.  
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Fig. 10. IL-1R2 expression in brain. Real-time RT-PCR was used to quantify expression in 
brains of mice fed LFD or HFD for 12 weeks and in mice fasted for 24 hours.  Results are 
expressed as relative change in mRNA expression, means ± SEM; n = 8 per group; **p < 0.005 
LFD fasted vs HFD fasted; 
b
p < 0.005, LFD fed vs LFD fasted.  
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Fig. 11. IL-1R1 expression in brain Real-time RT-PCR was used to quantify expression in 
brains of mice fed LFD or HFD for 12 weeks and in mice fasted for 24 hours.  Results are 
expressed as relative change in mRNA expression, means ± SEM; n = 8 per group; *p < 0.05, 
LFD fed vs HFD fed; LFD fasted vs HFD fasted. 
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Fig. 12. IL-1RA expression in brain.  Real-time RT-PCR was used to quantify expression in 
brains of mice fed LFD or HFD for 12 weeks and in mice fasted for 24 hours.  Results are 
expressed as relative change in mRNA expression, means ± SEM; n = 8 per group; *p < 0.05, 
LFD fed vs HFD fed.  
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Fig. 13. Saccharin preference is decreased in IL-1RA KO mice.  IL-1RA KO and WT mice 
were fed LFD and saccharin preference was measured utilizing a 2-bottle test for 5 days. Results 
are expressed as a percentage of daily consumption over 5 days, means ± SEM; n = 4, *p < 0.005, 
IL-1RA KO water vs WT water; IL-1RA KO saccharin vs WT saccharin; WT water vs 
saccharin; IL-1RA KO water vs saccharin. 
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42,791.6 ± 4719 b43,844.52 ± 1954.7 b
IL -1RA
8,118.8±680.3 a 3,104.5 ±292.8 aLeptin
FedFasted
Table 1
Leptin (pg/mL), IL-1RA (ng/mL), and IL-1β concentrations for LFD and HFD fed/fasted mice
Fed Fasted
IL -β
796.42 ±92.07 800.79 ± 81.51 b567.12 ±17.39 a 701.33 ±54.07
nd nd nd nd
LFD HFD
a a
 
 
Table 1. Serum leptin and IL-1RA is increased in HFD fed mice. Mice were fed 10% fat (LFD) 
for 6 weeks or 60% fat (HFD) for 12 weeks and serum leptin, IL-1RA, and IL-1β was measured 
by ELISA. Nd indicate “not determined.”  Results are expressed as mean ±SEM, n=8. Within a 
row, different letter superscripts indicate significant differences, p<0.05. 
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LFD
Fed
Table 2
Fasted
30.8 ± 25.2 ± 0.3 
HFD 49.7 ± 0.9c 47.2 ± 0.8d
Body weights for fed/fasted mice fed HFD or LFD
b0.6a
 
 
Table 2. Body weights for fed and fasted mice on a HFD or LFD.  Body weights were taken 
from mice fed a LFD or HFD during the fed state and after a 24 hour fast.  Results are expressed 
as a mean ± SEM, n=8 per group, different letter superscripts indicate significant differences, 
p<0.05.  
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LFD
Fed
Table 3
Fasted
147.7 ± 70 ± 1.3b
HFD 176.0 ± 6.7c 121 ± 6.7d
5.4a
Blood glucose for fed/fasted mice fed HFD or LFD
 
 
Table 3. Blood glucose for fed/fasted mice on a HFD or LFD.  Blood glucose was measured in 
mice fed a LFD or HFD during the fed state and after a 24 hour fast.  Results are expressed as a 
mean ± SEM, n=8 per group, different letter superscripts indicate significant differences, 
p<0.001.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 44 
 
CHAPTER FIVE  
CONCLUSIONS 
 Anhedonia is defined as an inability to experience pleasure from normally pleasurable 
events.  It can manifest in rodent behavior as a decreased preference for highly palatable 
solutions, and can be easily measured (Dantzer, 2001).  It is a symptom of sickness behavior and 
depression, which is a normal response of the host to pathogens that are recognized by the innate 
immune system (Dantzer, 2001).  Typically, systemic or central infusion of cytokines or 
endotoxins such as LPS, induce symptoms of sickness behavior in experimental animals and 
human beings, including anhedonia.  In the absence of an exogenous immune stimulus, as is the 
case in Fig. 1, anhedonia is present in mice that are fed HFD containing 60% of total calories 
from fat for 12 weeks.  The question that arises is whether this behavioral deficit is due to the 
low-grade inflammation that has been reported in rodent obesity (Hotamisligil et al., 1993; Xu et 
al., 2003), a dysregulation of specific cytokines in obesity, particularly IL-1β/IL-1RA (Matsuki 
et al., 2003), or a direct effect of increased levels of leptin or leptin resistance.   
Other behavioral measures of depressed mood such as a decreased interest in physical 
surroundings may occur in a typical host response to infection/inflammation as well (Dantzer, 
2001).  A typical measurable behavior in rodents is burrowing.  Rodents are noted for their 
burrowing ability which is probably an extremely ancient behavior (Deacon, 2006).  Observation 
of this behavior shows that mice dig the burrowing material out of their designated burrows with 
coordinated hind- and forelimb movements and kick them outside the container, rather than carry 
the pellets carefully to a selected spot which could be interpreted as hoarding.  It is possible that 
burrowing is related to tunnel maintenance, as the filled burrow may represent a blocked tunnel, 
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or it could reflect elements of defensive behavior in that a rodent would typically attempt to 
prevent predators from entering their burrows by digging and kicking debris toward an intruder.  
Defensive burrowing is a well-known paradigm for measuring anxiety (Pinel et al., 1978).  Rat 
and mouse burrowing is decreased after administration of LPS and IL-1β –expressing 
replication-deficient adenovirus (Deacon, 2006).  It has also been shown as a way of assessing 
recovery from surgery, in that an animal that is even slightly ill will show reduced burrowing.  I 
have shown that burrowing behavior is significantly decreased in mice fed a HFD compared to 
mice fed a LFD at both 2 and 24 hours as seen in Fig. 4.  This suggests that there is some 
behavioral dysfunction due to HFD feeding.  It is possible that these animals are experiencing 
sickness syndrome or depressed mood.  Interestingly, when fasted for 24 hours, as seen in Fig. 6, 
burrowing increases in HFD fed mice at 2 and 24 hours respectively, and is comparable to 
burrowing observed in mice fed LFD.  Taken together, these results suggest a behavioral benefit 
of fasting in HFD fed mice.   
A third behavioral test was employed as seen in Fig. 7. The FST is based upon the 
observation that “rodents eventually develop immobility when they are placed in a cylinder of 
water after they cease active escape behaviors (Cryan et al., 2005b).”  Unlike the previous 
behavioral tests, there is no significant difference in time spent immobile in mice fed HFD 
compared to mice fed LFD.  Interestingly though, when both groups of mice are fasted (Fig. 7), 
immobility is decreased, to a somewhat greater extent in mice fed a HFD.  This would suggest 
that physiological changes that occur during fasting may contribute antidepressant action to both 
groups of mice regardless of diet, but to a slightly increased extent in mice fed HFD.   
Leptin modulates inflammation (Faggioni et al., 2001) and has been shown to be 
increased in rodents fed HFD (Lin et al., 2000).  It has also been associated with the modulation 
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of motivation to obtain reward (Figlewicz et al., 2008) and anti-depressant-like activity (Lu, 
2007).  Serum leptin was measured in mice fed HFD and LFD.  As expected, leptin was 
significantly higher in mice fed a HFD.  The hypothesis that elevated levels of leptin may 
attenuate response to a reward was tested by promoting negative energy balance by fasting mice 
for 24 hours.  Negative energy balance has previously been shown to promote response to foods 
and other reinforcements (Figlezwicz et al., 2008); therefore, serum leptin was also measured 
after a 24 hour fast to delineate whether or not a significant decrease in serum leptin contributed 
to the increased response to saccharin consumption, burrowing activity, and FST.  Results 
indicate that leptin was not significantly decreased in fasted HFD fed mice (Table 1), so it is 
likely that serum leptin did not contribute to an increase in response to stimuli in this experiment. 
  Given that IL-1RA levels are typically elevated in obese rodents as our lab has 
previously shown, as well as in the circulation of patients with inflammatory conditions (Arend, 
2002) and because the balance between IL-1RA and IL-1β influences the course, susceptibility 
and severity to many diseases, we measured IL-1RA and IL-1β in the serum (Table 1).  Leptin 
has been shown to increase peripheral IL-1RA and also induces its expression in the 
hypothalamus.  We hypothesized that IL-1RA (or more likely IL-1 balance) may be contributing 
to the behavioral consequences of HFD feeding.  However, while IL-1RA was increased in mice 
fed a HFD compared to mice fed a LFD, a 24 hour fast did not significantly change the serum 
concentration.  IL-1β was not detected in the serum of any group.  The lowest concentration of 
detection of the assay used was 7.8 pg/mL.  This indicates that peripheral IL-1RA/IL-1β balance 
likely did not have an effect on the consequential behaviors observed.   
Both leptin and IL-1RA can cross the BBB (Guitierrez et al., 1994) and leptin induces IL-
1RA expression in the brain, including the hypothalamus (Hosoi et al., 2002).  Therefore, we 
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measured expression of these two cytokines and their receptors, as well as IL-1α and IL-1β in the 
brain. As shown in Fig. 12 and 11 respectively, in mice fed a HFD, IL-1RA was increased in the 
fed state, and IL-1R1 decreased compared to LFD fed mice.  The only significant change due to 
fasting within the HFD group was an increase in leptin expression.  This may indicate an 
increased central leptin sensitization in HFD mice that are fasted, which is important because the 
brain is a target site for leptin to exert its mood promoting actions (Figelwicz et al., 2008).  These 
results indicate differences in fed state cytokine expression between HFD and LFD mice, and 
that leptin expression in the brain is influenced by 24 hour fasting, possibly contributing to the 
behavioral benefit of a 24 hour fast on HFD fed mice.   
Since IL-1RA expression is increased in mice fed HFD, who exhibit saccharin aversion 
and decreased burrowing compared to mice fed LFD, saccharin preference was tested in IL-1RA 
knockout mice (Fig. 13).  We have hypothesized that physiologically balanced IL-1/IL-1RA 
concentrations may be important in normal mouse behaviors.  IL-1RA knockout mice display a 
decreased preference for saccharin solution (Fig. 13), similar to HFD mice, indicating that a 
deviation from normal physiological levels of IL-1RA may contribute to anhedonic behaviors.  
However, IL-1RA knockouts also have low levels of leptin, (about 6-fold decreased) compared 
to control mice (Somm et al., 2005), which could be the cause for anhedonic behavior. 
To further complicate things, when fasted, IL-1RA expression in the brain of HFD mice 
trends toward increasing contrary to our expectations, and we observe increased saccharin 
preference, increased burrowing, and decreased immobility in the FST.  Therefore, it is probably 
not the case that fluctuations in IL-1RA or IL-1 balance contributes to the behavioral changes 
observed in fasted mice fed HFD, but more likely a contribution of increased brain based leptin.  
Taken together, these findings indicate that changes in brain expression of specific genes, 
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particularly leptin occur simultaneously with the behavioral benefits observed in fasted mice fed 
HFD.   
To further probe the mechanism of why these behavioral consequences exist in mice fed 
a HFD, ICV leptin could be infused continuously over the course of a 5 day saccharin preference 
test, to establish if central leptin infusion increases preference for saccharin.  Both burrowing and 
FST should also be examined with leptin infusion to see if behavior changes resemble those in 
fasted HFD fed mice.  Another set of experiments could include measuring burrowing and FST 
in IL-1RA knockout mice and then injecting leptin ICV and repeating the procedures to see if 
exogenous brain leptin improves behavioral dysfunction.  The corollary experiment of the HFD 
study would be to examine the neuropeptides that are increased during fasting.  Here we have 
specifically chosen to examine leptin’s role, but other neuropeptides may be increased during 
fasting including orexin, ghrelin, melanin-concentrating hormone and neuropeptide-y.  
Interestingly, ghrelin has been shown to play a significant role in neurotrophy, particularly in the 
hippocampus, and is essential for cognitive adaptation to changing environments and the process 
of learning (Atcha et al., 2009). These could be candidates for further study. 
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